Tejnaksh Healthcare Limited has issued a formal response to the Bombay Stock Exchange (BSE) regarding a clarification sought on significant movement in the company's share price. The response, dated April 9, 2026, addresses concerns raised by the exchange about recent price volatility.

Company's Response to BSE Inquiry

The healthcare company received a clarification request from BSE on April 8, 2026, with reference number L/SURV/ONL/PV/APJ/2026-2027/3536. In its response, the company categorically stated that there is no material information or disclosure that has been withheld from stock exchanges in the recent past.

Regulatory Compliance Statement

Tejnaksh Healthcare emphasized its commitment to regulatory compliance, stating that it has been diligently disclosing all material information to various stakeholders. The company confirmed that it has been duly complying with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015.

The management further assured that the company will continue to disclose any material information whenever required, maintaining transparency with investors and regulatory bodies.

Market-Driven Price Movement

Regarding the share price volatility that prompted the BSE inquiry, the company attributed the movement to prevailing market conditions. The management stated that the price movement is "purely due to market conditions and absolutely market driven," indicating no company-specific factors behind the recent fluctuations.

The response was signed by Dr. Ashish V. Rawandale, Managing Director (DIN: 02005733), who digitally authenticated the document on April 9, 2026, at 23:09:06 +05'30'.

Tejnaksh Healthcare Limited has submitted its unaudited financial results for the quarter and nine months ended December 31, 2025, under Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company's Board of Directors approved both consolidated and standalone results at their meeting held on February 07, 2026, following review and recommendation by the Audit Committee.

Consolidated Financial Performance

The company's consolidated operations showed mixed performance during the quarter. Revenue from operations declined to ₹261.62 lakhs in Q3FY26 compared to ₹318.98 lakhs in the corresponding quarter of the previous year.

For the nine-month period, consolidated revenue from operations was ₹823.40 lakhs compared to ₹968.22 lakhs in the previous year. Net profit for the nine months stood at ₹83.24 lakhs against ₹180.72 lakhs in the corresponding period last year.

Standalone Financial Results

On a standalone basis, the company reported revenue from operations of ₹169.08 lakhs for Q3FY26, down from ₹223.82 lakhs in Q3FY25. Net profit on standalone basis was ₹22.78 lakhs compared to ₹71.94 lakhs in the previous year quarter.

For the nine-month standalone period, revenue from operations was ₹540.66 lakhs versus ₹639.35 lakhs in the previous year, while net profit stood at ₹87.56 lakhs compared to ₹186.61 lakhs.

Operational Highlights

The company operates primarily in the medical and healthcare services segment. Key expense categories during Q3FY26 included employee benefits expense of ₹33.41 lakhs on consolidated basis and ₹17.98 lakhs on standalone basis. Other expenses constituted a significant portion at ₹134.49 lakhs for consolidated operations.

The company maintained its paid-up equity share capital at ₹1,015.68 lakhs with a face value of ₹5 per share.

Regulatory Compliance and Audit

The financial results were prepared in accordance with Indian Accounting Standards (Ind AS) and comply with SEBI Listing Obligations and Disclosure Requirements Regulations, 2015. The statutory auditors, Maheshwari & Co., conducted a limited review of both consolidated and standalone results without any modifications to their review reports.

The company noted that the Government of India's consolidation of 29 existing labour legislations into four unified labour codes on November 21, 2025, had no material impact on employee benefit expenses for the reporting period. The results include the parent company Tejnaksh Healthcare Limited and its subsidiary Tej Vedaant Healthcare Private Limited.